[go: up one dir, main page]

NO992102D0 - Peptide composition, as well as pharmaceutical composition and cancer vaccine including the peptide composition - Google Patents

Peptide composition, as well as pharmaceutical composition and cancer vaccine including the peptide composition

Info

Publication number
NO992102D0
NO992102D0 NO992102A NO992102A NO992102D0 NO 992102 D0 NO992102 D0 NO 992102D0 NO 992102 A NO992102 A NO 992102A NO 992102 A NO992102 A NO 992102A NO 992102 D0 NO992102 D0 NO 992102D0
Authority
NO
Norway
Prior art keywords
composition
peptide composition
well
peptide
cancer vaccine
Prior art date
Application number
NO992102A
Other languages
Norwegian (no)
Other versions
NO309798B1 (en
NO992102L (en
Inventor
Jon Amund Eriksen
Marianne Klemp Gjertsen
Gustav Gaudernack
Ller Mona M
Original Assignee
Norsk Hydro As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norsk Hydro As filed Critical Norsk Hydro As
Priority to NO19992102A priority Critical patent/NO309798B1/en
Publication of NO992102D0 publication Critical patent/NO992102D0/en
Priority to AU44389/00A priority patent/AU4438900A/en
Priority to JP2000615037A priority patent/JP2002543149A/en
Priority to PCT/NO2000/000142 priority patent/WO2000066153A1/en
Priority to EP00925746A priority patent/EP1173199A1/en
Priority to CA002372187A priority patent/CA2372187A1/en
Priority to ARP000102059A priority patent/AR023806A1/en
Publication of NO992102L publication Critical patent/NO992102L/en
Publication of NO309798B1 publication Critical patent/NO309798B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO19992102A 1999-04-30 1999-04-30 Peptide composition, as well as pharmaceutical composition and cancer vaccine including the peptide composition NO309798B1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
NO19992102A NO309798B1 (en) 1999-04-30 1999-04-30 Peptide composition, as well as pharmaceutical composition and cancer vaccine including the peptide composition
AU44389/00A AU4438900A (en) 1999-04-30 2000-04-28 Ras oncogen p21 peptide vaccines
JP2000615037A JP2002543149A (en) 1999-04-30 2000-04-28 RAS oncodin p21 peptide vaccine
PCT/NO2000/000142 WO2000066153A1 (en) 1999-04-30 2000-04-28 RAS ONCOGEN p21 PEPTIDE VACCINES
EP00925746A EP1173199A1 (en) 1999-04-30 2000-04-28 RAS ONCOGEN p21 PEPTIDE VACCINES
CA002372187A CA2372187A1 (en) 1999-04-30 2000-04-28 Ras oncogen p21 peptide vaccines
ARP000102059A AR023806A1 (en) 1999-04-30 2000-04-28 USE OF A PEPTIDE MIXTURE FOR THE MANUFACTURE OF A THERAPEUTIC AGENT FOR PROFILAXIS AND / OR CANCER TREATMENT, PHARMACEUTICAL COMPOSITIONS AND VACCINES CONTAINING SUCH MIXTURE AND THE PROCEDURES FOR PREPARATION OF THESE COMPOSITIONS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NO19992102A NO309798B1 (en) 1999-04-30 1999-04-30 Peptide composition, as well as pharmaceutical composition and cancer vaccine including the peptide composition

Publications (3)

Publication Number Publication Date
NO992102D0 true NO992102D0 (en) 1999-04-30
NO992102L NO992102L (en) 2000-10-31
NO309798B1 NO309798B1 (en) 2001-04-02

Family

ID=19903274

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19992102A NO309798B1 (en) 1999-04-30 1999-04-30 Peptide composition, as well as pharmaceutical composition and cancer vaccine including the peptide composition

Country Status (7)

Country Link
EP (1) EP1173199A1 (en)
JP (1) JP2002543149A (en)
AR (1) AR023806A1 (en)
AU (1) AU4438900A (en)
CA (1) CA2372187A1 (en)
NO (1) NO309798B1 (en)
WO (1) WO2000066153A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2836684B1 (en) * 2002-03-04 2004-12-17 Inst Nat Sante Rech Med RAS MUTED PEPTIDES AND THEIR USE IN IMMUNOTHERAPY
WO2004058157A2 (en) 2002-12-16 2004-07-15 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
US8343502B2 (en) 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
CA2647102A1 (en) 2006-03-27 2007-11-22 Globeimmune, Inc. Ras mutation and compositions and methods related thereto
GB0821616D0 (en) 2008-11-26 2008-12-31 Lytix Biopharma As Compounds
CN104548089B (en) * 2009-09-03 2017-09-26 辉瑞疫苗有限责任公司 PCSK9 vaccines
WO2011143656A2 (en) 2010-05-14 2011-11-17 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
CN102060929A (en) * 2010-06-07 2011-05-18 夏书奇 T-cell immune balance peptide
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
KR20160097290A (en) 2013-12-09 2016-08-17 타르고바스 에이에스에이 A peptide mixture
CN106456724A (en) 2013-12-20 2017-02-22 博德研究所 Combination therapy with neoantigen vaccine
KR20170002563A (en) * 2014-05-06 2017-01-06 타르고바스 에이에스에이 Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent
ES3049406T3 (en) 2014-12-19 2025-12-16 Broad Inst Inc Methods for profiling the t-cell-receptor repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
HK1252267A1 (en) * 2015-05-20 2019-05-24 The Broad Institute Inc. Shared neoantigens
WO2016202937A1 (en) * 2015-06-16 2016-12-22 Targovax Asa Mutated fragments of the ras protein
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
MX2019009070A (en) 2017-02-01 2019-10-30 Modernatx Inc Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides.
CN110709094A (en) * 2017-02-03 2020-01-17 威斯康星州医药大学股份有限公司 KRAS peptide vaccine compositions and methods of use
EP3606550A2 (en) 2017-04-03 2020-02-12 Neon Therapeutics, Inc. Protein antigens and uses thereof
WO2019126186A1 (en) 2017-12-18 2019-06-27 Neon Therapeutics, Inc. Neoantigens and uses thereof
MX2020014243A (en) 2018-06-19 2021-05-12 Biontech Us Inc NEOANTIGENS AND THEIR USES.
CN114681600A (en) * 2018-10-19 2022-07-01 杭州纽安津生物科技有限公司 Universal polypeptide vaccine and application thereof in preparation of medicine for treating/preventing pancreatic cancer
US20220313803A1 (en) * 2019-01-07 2022-10-06 Brightpath Biotherapeutics Co., Ltd. Novel neoantigens and cancer immunotherapy using same
IL266728B (en) * 2019-05-19 2020-11-30 Yeda Res & Dev Identification of recurrent mutated neopeptides
WO2021165453A1 (en) * 2020-02-19 2021-08-26 Aelin Therapeutics Molecules targeting proteins
US20230090247A1 (en) * 2020-02-19 2023-03-23 Aelin Therapeutics Molecules targeting ras protein
WO2022219152A1 (en) * 2021-04-16 2022-10-20 Oblique Therapeutics Ab Kras antibodies
JP2025538524A (en) * 2022-11-22 2025-11-28 エリクサージェン セラピューティクス，インコーポレイティド Antigens for Cancer Immunotherapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957859A (en) * 1988-02-16 1990-09-18 Hoffmann-La Roche Inc. Antibodies for transforming ras protein
GB9103974D0 (en) * 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
AU2734397A (en) * 1996-04-19 1997-11-12 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Mutated ras peptides for generation of cd8+ cytotoxic t lymphocytes
GB9620350D0 (en) * 1996-09-30 1996-11-13 Maudsley David J Cancer vaccine
GB2328689A (en) * 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer

Also Published As

Publication number Publication date
WO2000066153A1 (en) 2000-11-09
CA2372187A1 (en) 2000-11-09
NO309798B1 (en) 2001-04-02
EP1173199A1 (en) 2002-01-23
AR023806A1 (en) 2002-09-04
JP2002543149A (en) 2002-12-17
NO992102L (en) 2000-10-31
AU4438900A (en) 2000-11-17

Similar Documents

Publication Publication Date Title
NO992102L (en) Peptide composition, as well as pharmaceutical composition and cancer vaccine including the peptide composition
NL1015859A1 (en) Pharmaceutical preparations.
NO20032438D0 (en) Ortho and Metasubstituted Bis-Aryl Compounds, Their Preparation and Use, and Pharmaceutical Preparations Containing the Compounds
DK1210113T3 (en) Combined vaccine preparations
ITTO20010005A0 (en) PHARMACEUTICAL FORMULATION.
NO20033556D0 (en) Pharmaceutical preparations
EE200200038A (en) Preserved pharmaceutical preparations
TR199901077A3 (en) Pharmaceutical formulations.
KR20050009999A (en) Pharmaceutical preparations
NO20015175D0 (en) Pharmaceutical composition
ATE490327T1 (en) VACCINE COMPOSITION
ZA200407868B (en) 17alpha-Alkyl-17beta-oxy-estratrienes, uses thereof and pharmaceutical preparations.
NO20006138D0 (en) Substituted indolinones, preparation and use thereof as drugs
NO20005146D0 (en) Thienylazolylalkoxyethanamines, their preparation and their use as drugs
NO20022606L (en) Pharmaceutical combinations
NO20016247D0 (en) Streptogramin derivatives, their preparation and preparations containing the derivatives
IT1311921B1 (en) PHARMACEUTICAL COMPOUNDS.
NO20022022D0 (en) N-guanidinoalkylamides, their preparation, their use and pharmaceutical compositions comprising these
NO983472D0 (en) Taxoids, their preparation and pharmaceutical preparations containing the taxoids
DE69926012D1 (en) PHARMACEUTICAL PREPARATIONS
DK1118610T3 (en) Benzenesulfonamide derivatives, process for their preparation and pharmaceutical compositions containing the derivatives
FI4488U1 (en) Pharmaceutical composition
AR025867A1 (en) PHARMACEUTICAL PORTASDORA FORMULATION
NO20014692D0 (en) 3-amidinobenzenesulfonamide derivatives, medical compositions containing them and intermediates in the preparation thereof
NO20016430L (en) Pharmaceutical complex

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ZACCO NORWAY AS POSTBOKS 765 SENTRUM OSLO, 0106 NO

MM1K Lapsed by not paying the annual fees